Welcome to our dedicated page for INNOSPEC SEC filings (Ticker: IOSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innospec Inc. filings document the financial reporting, governance and capital-return disclosures of a specialty chemicals operating company. Form 8-K reports record quarterly and annual results, segment commentary for Performance Chemicals, Fuel Specialties and Oilfield Services, Regulation FD disclosures, semi-annual dividends and board-authorized common stock repurchase programs.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation votes, auditor ratification and related governance procedures. Its filings also identify IOSP common stock as a NASDAQ-listed security and provide formal disclosure around results of operations, financial condition, risk-related business context and shareholder voting matters.
Vanguard Portfolio Management reported beneficial ownership of 1,870,254 shares of Innospec Inc common stock, equal to 7.51% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 1,870,254 shares and sole voting power for 10,163 shares. The filing notes holdings include securities held for Vanguard funds and client accounts managed by affiliates.
Innospec Inc Schedule 13G/A amendment: The Vanguard Group reports beneficial ownership of 0 shares (0%) of Common Stock in Amendment No. 12. The filing notes an internal realignment of Vanguard and that certain subsidiaries now report ownership separately in reliance on SEC Release No. 34-39538.
Innospec Inc. has called its 2026 annual meeting of stockholders for May 8, 2026, at The St. Regis New York. Stockholders of record on March 13, 2026, when 24,890,467 common shares were outstanding, may vote.
They will elect two Class I directors to terms ending in 2029, cast an advisory vote on executive compensation, and ratify the independent auditor. The proxy describes a strongly independent board with a separate non-executive chair, anti-hedging and anti-pledging policies, majority-vote resignation guidelines, and director stock ownership requirements.
Innospec also highlights sustainability and human-capital initiatives, including reduced scope 1 and 2 emissions versus 2014, global safety programs, extensive compliance training, and community and employee engagement, while detailing non‑employee director fees and equity-based compensation.
INNOSPEC INC. director Milton C. Blackmore reported amended details of recent stock sales. On February 27, 2026, he completed two open-market sales of the company’s common stock totaling 594 shares. One block of 287 shares was sold at a weighted average price of $76.30 per share, and another 307 shares at a weighted average price of $76.79 per share. After these transactions, his directly held stake changed in two steps to 10,837 shares and then 10,530 shares of common stock. This amended Form 4 corrects previously reported transaction prices and notes that the sale prices reflect weighted averages across multiple trades within stated ranges.
Innospec Inc. director Larry Padfield reported amended insider sales of company common stock. The Form 4/A corrects transaction prices previously reported. On February 27, 2026, he sold 287 shares at $76.30 and 307 shares at $76.79 in open-market transactions, totaling 594 shares.
The footnotes explain that each reported price is a weighted average. The 287-share sale occurred in multiple trades between $75.5001 and $76.55, and the 307-share sale in trades between $76.555 and $77.0713. After these transactions, his directly held ownership was reported as 9,453 shares of Innospec common stock.
Innospec Inc. director Claudia Poccia reported amended insider stock sales. The Form 4/A corrects transaction prices previously reported for two open-market sales of Innospec common stock on February 27, 2026.
The amended filing shows sales totaling 119 shares, with 57 shares sold at a weighted average price of $76.30 and 62 shares sold at a weighted average price of $76.79. After these transactions, Poccia directly owned 6,508 shares of Innospec common stock.
The footnotes explain that each reported price is a weighted average and that the shares were sold in multiple transactions, with individual prices ranging from $75.5001 to $76.55 for the first sale and from $76.555 to $77.0713 for the second sale. Poccia has undertaken to provide full trade details, including exact share amounts and prices for each execution, to the SEC staff, Innospec, or any Innospec security holder upon request.
Innospec Inc. director David Landless reported selling 594 shares of common stock in two open-market transactions. On February 27, 2026, he sold 287 shares at a weighted average price of $76.30 and 307 shares at a weighted average price of $76.79.
This amended Form 4 corrects the previously reported transaction prices and states that the prices reflect weighted averages. The first sale occurred in multiple trades between $75.5001 and $76.55, and the second between $76.555 and $77.0713. Following these sales, he directly holds 7,632 shares.
Innospec Inc. executive Ian Cleminson, EVP & CFO, reported amended insider stock sales. On February 27, 2026, he sold a total of 2,380 shares of Innospec common stock in two open-market transactions at weighted average prices of $76.30 and $76.79 per share. After these sales, he directly owned 20,357 shares of common stock. The amendment corrects previously reported transaction prices and notes the shares were sold in multiple trades within price ranges from $75.5001 to $76.55 and from $76.555 to $77.0713.
Innospec Inc. director Milton C. Blackmore reported an open-market sale of 594 shares of Innospec common stock. The transaction took place on February 27, 2026 at a price of $76.5562 per share. After this sale, he directly owns 10,530 shares of Innospec.